Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) saw a large drop in short interest in December. As of December 29th, there was short interest totalling 2,100,230 shares, a drop of 37.5% from the December 15th total of 3,360,228 shares. Based on an average daily trading volume, of 506,045 shares, the days-to-cover ratio is currently 4.2 days. Approximately 3.4% of the company’s shares are sold short.

Shares of Aralez Pharmaceuticals (NASDAQ ARLZ) opened at $1.78 on Monday. Aralez Pharmaceuticals has a twelve month low of $0.95 and a twelve month high of $4.66. The firm has a market cap of $119.06, a PE ratio of -1.05 and a beta of 1.37. The company has a current ratio of 1.00, a quick ratio of 0.92 and a debt-to-equity ratio of 4.64.

Aralez Pharmaceuticals (NASDAQ:ARLZ) last announced its quarterly earnings data on Thursday, November 9th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.02. Aralez Pharmaceuticals had a negative net margin of 112.89% and a negative return on equity of 118.13%. The company had revenue of $24.30 million during the quarter, compared to analyst estimates of $22.87 million. During the same quarter last year, the business posted ($0.32) EPS. The firm’s revenue for the quarter was up 78.7% on a year-over-year basis. equities analysts forecast that Aralez Pharmaceuticals will post -1.54 earnings per share for the current fiscal year.

In related news, Director Arthur S. Kirsch acquired 50,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was bought at an average price of $1.47 per share, for a total transaction of $73,500.00. Following the acquisition, the director now directly owns 271,609 shares of the company’s stock, valued at approximately $399,265.23. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.70% of the company’s stock.

Large investors have recently bought and sold shares of the company. Ballentine Partners LLC raised its holdings in shares of Aralez Pharmaceuticals by 166.7% in the 3rd quarter. Ballentine Partners LLC now owns 80,000 shares of the company’s stock valued at $183,000 after purchasing an additional 50,000 shares in the last quarter. Isthmus Partners LLC raised its holdings in shares of Aralez Pharmaceuticals by 0.8% in the 2nd quarter. Isthmus Partners LLC now owns 154,387 shares of the company’s stock valued at $208,000 after purchasing an additional 1,285 shares in the last quarter. Intrinsic Edge Capital Management LLC bought a new stake in shares of Aralez Pharmaceuticals in the 2nd quarter valued at about $270,000. Brown Advisory Securities LLC bought a new stake in shares of Aralez Pharmaceuticals in the 3rd quarter valued at about $394,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Aralez Pharmaceuticals by 71.3% in the 3rd quarter. Wells Fargo & Company MN now owns 273,130 shares of the company’s stock valued at $625,000 after purchasing an additional 113,720 shares in the last quarter. Institutional investors and hedge funds own 19.41% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Aralez Pharmaceuticals Inc (ARLZ) Short Interest Update” was originally reported by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/01/15/aralez-pharmaceuticals-inc-arlz-short-interest-update.html.

Aralez Pharmaceuticals Company Profile

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.